Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions

A technology for inflammatory diseases and calcitonin, applied in allergic diseases, drug combinations, skin diseases, etc., can solve problems such as weakened anti-inflammatory effects

Inactive Publication Date: 2008-05-14
QUEEN MARY UNIV OF LONDON
View PDF14 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, as mentioned above, long-term treatment with GCs involves secondary osteoporosis, so the beneficial anti-inflammatory effects of GCs are undercut by their severe effects on bone erosion

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions
  • Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions
  • Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0087] Example 1: A Study of the Effect of a Treatment Regime for Experimentally Induced Arthritis

[0088] Collagen II-induced arthritis (CIA). Female Lewis rats (body weight 150±20g; HarlanUK Ltd Bicester, Oxfordshire, England) were fed with standard feed, free to drink water, and kept in a 12-hour light / dark cycle. Animal manipulations were performed under license from the Home Office under the Animals Act (Scientific Procedures, 1986). Bovine nasal collagen II (4 mg / ml; Sigma-Aldrich Ltd, Poole, UK) was dissolved in acetic acid (0.01 M) and emulsified with an equal volume of ice-cold incomplete Freund's adjuvant (Sigma-Aldrich). On day 0, rats were anesthetized with halothane, the tail tip was clipped, and collagen II / adjuvant suspension (400 μg collagen II per mouse) was intradermally injected. On days 11 to 13, the first symptoms of arthritis were evident, and the strongest inflammatory response was observed on days 18 to 21.

[0089] CIA-induced inflammation is limit...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides the use of a calcitonin in the preparation of a medicament for the treatment of an inflammatory disease or condition. The calcitonin may be selected from the group consisting of human, salmon, eel, porcine, bovine, or chicken calcitonin or a derivative, a fragment or a variant thereof. The inflammatory disease or condition may be rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), osteoarthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis (AS), lupus erythamatosis, multiple sclerosis (MS), asthma, or immuno-suppressive therapy (e.g. post transplantation surgery). The treatment may also comprise administration of a glucocorticoid, an anti-rheumatic drug or an antibody.

Description

technical field [0001] The present invention relates to the use of calcitonin as a combination therapy for the management of inflammatory pathologies and arthritic rashes. Background technique [0002] Glucocorticoid drugs (GCs), potential immunosuppressants and anti-inflammatory agents, have been used therapeutically in several inflammatory pathologies. Control of symptoms of rheumatoid arthritis and other rheumatic conditions is often required in long-term therapy with GCs. Recent evidence suggests that GCs have disease-modifying effects in addition to their known anti-inflammatory effects. However, the therapeutic management of pathology with long-term use of GCs often involves a host of unwanted side effects, including the hypothalamic-pituitary-adrenal axis, the cardiovascular system, and fat and bone metabolism. In particular, secondary osteoporosis is one of the major problems associated with long-term GC therapy in patients with rheumatoid arthritis. Several mecha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/00A61K38/23
CPCA61K38/23A61P17/06A61P19/02A61P19/10A61P25/00A61P29/00A61P37/02A61P37/06A61P43/00
Inventor 伊恩·麦金太尔莫罗·佩雷蒂露西娅·曼奇尼
Owner QUEEN MARY UNIV OF LONDON
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap